ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) operates as a biopharmaceutical company focused on developing targeted antiviral therapies. The company has two drug candidates in clinical studies. The first, FV-100, is now in phase III trials and being developed for the treatment of herpes zoster, or shingles and shingle pain. The second, CMX157, is a highly potent analog of the successful antiviral drug tenofovir DF (Viread). For more information, visit the company’s website at www.contravir.com.
ContraVir Pharmaceuticals (CTRV) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option